The organ-on-a-chip developer Emulate has raised $82 million to boost its offerings aimed at replicating human biology through easier-to-manage in vitro cellular models. Used in past drug development ...
Emulate, Inc., a leading provider of next generation in vitro models, has launched the Zoë-CM2™ Culture Module, a second-generation Zoë instrument that is at the core of their Human Emulation System®.
Organ-on-a-chip developer Emulate has gathered $36 million in series C financing, and plans to expand its platform to include a wider range of disease models for drug efficacy testing. The ...
Emulate Inc. has launched a new adeno-associated virus (AAV) transduction application for the Liver-Chip that enables gene therapy researchers to test the delivery efficiency and safety of AAV vectors ...
BELLEVUE, Wash.--(BUSINESS WIRE)--EMulate Therapeutics, Inc. (EMulate) announced today the publication of its peer-reviewed clinical trial using EMulate’s technology for the treatment of glioblastoma ...
New study published in Journal of Electromagnetic Biology and Medicine provides additional validation for Company’s technology and business model ...
DUBLIN--(BUSINESS WIRE)--The "Organ-On-Chip Global Market 2018" report has been added to Research and Markets' offering. The global market for OOCs was valued at $20 million in 2016. It is expected to ...
(MENAFN- GlobeNewsWire - Nasdaq) Dublin, April 11, 2025 (GLOBE NEWSWIRE) -- The "Organ-on-a-Chip: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report analyzes ...
Preclinical animal and cellular models are notoriously bad at predicting drug candidate toxicity in humans. Animal biology is often fundamentally different on that front than in humans, while cells in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback